Access and Support

Committed to connecting patients with support

Your patients aren’t alone on their treatment journey. EMD Serono offers a network of support services to help eligible patients access and afford treatment.
Mixed ethnicity male talking on smartphone, not actual Serostim<sup>®</sup> patient
AXIS Center logo with telephone number and open hours

The AXIS Center®: a reimbursement and support program dedicated to patients taking Serostim®

A dedicated
Case Manager

who will be the single point of contact for the patient and their care team

Financial assistance programs

that may help cover costs related to Serostim® prescriptions


offering $0
costs for most commercially insured patients


to answer all Serostim® product-related questions

Icon-#1 Copy 4

Injection training*

on how to reconstitute and administer Serostim® and properly dispose of needles and syringes

The AXIS Center® strives to maintain a record of positively impacting patients by managing prior authorizations successfully and giving you the resources you need to overturn denied cases through appeals. The program is committed to assisting eligible patients whose insurance has denied approvals, as appropriate.

Case Managers, the single point of contact for eligible patients and their care team, are available to help with prior authorizations and other access concerns. Product Support Specialists are also available to address questions about the product and administration. Once enrolled, patients can call 1-877-714-AXIS (2947) to connect with the AXIS Center® Monday through Friday, 8 AM to 8 PM ET.

*An injection-training order is required. If injection training is requested, the patient’s provider will be contacted to create the order prior to any training being scheduled.
AXIS Center logo

Enroll your appropriate patients in the AXIS Center®

Start the enhanced enrollment process for your appropriate patients by clicking the link below.

The AXIS Center® utilizes CoverMyMeds® technology and support.

Programs to help your patients save on prescription cost

Serostim® Copay Assistance Program

  • For eligible commercially or privately insured patients
  • Can decrease or potentially eliminate out-of-pocket costs
  • Card can be used at all pharmacies in the Serostim® Secured Distribution Pharmacy Network. For a list of pharmacies, visit

Help your patients sign up for the Serostim® Copay Assistance Program and download their copay card.

†Subject to eligibility; restrictions apply.

Serostim<sup>®</sup> copay card
  • Patients must have a prescription drug benefit that covers Serostim® and a valid Serostim® prescription
  • Patients may not use the card if their private insurance, HMO, or other health or pharmacy benefit program paid for the entire Serostim® prescription
  • This is not an insurance program
  • Patients may not combine this card with any other rebate, coupon, free trial, or similar offer
  • Void in any state where prohibited by law, taxed, or otherwise restricted
  • EMD Serono reserves the right to rescind, revoke, or amend this offer at any time without notice

Patient Assistance Program

  • Eligible patients will receive Serostim® at no cost
  • To be eligible for the program, patients must meet certain financial and medical criteria
  • Patients who receive drug benefits for Medicaid, Medicare, or other federal or state programs are not eligible

To help your patients apply for the Patient Assistance Program, enroll them with the AXIS Center®.

†Subject to eligibility; restrictions apply.

Contact the AXIS Center®

Product Support Specialists and Case Managers are available at 1-877-714-AXIS (2947)
Monday through Friday, from 8 AM to 8 PM ET.

Helpful resources to support every step of the treatment journey

Key insights from HCPs who have experience treating with Serostim®

Important Safety Information and Indication


Acute Critical Illness:  Serostim® should not be initiated in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure.

Active Malignancy: Somatropin is contraindicated in the presence of active malignancy.  Any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin. Discontinue somatropin if there is evidence of recurrent activity.

Hypersensitivity: Serostim® is contraindicated in patients with a known hypersensitivity to somatropin or any of its excipients. Systemic hypersensitivity reactions have been reported.

Diabetic Retinopathy: Somatropin is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy.


Acute Critical Illness: Increased mortality (42% vs 19% in somatropin compared to placebo treated) in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported after treatment with pharmacologic amounts of somatropin.

Concomitant Antiretroviral Therapy: Somatropin has been shown to potentiate HIV replication in vitro, and there was no increase in virus production when antiretroviral agents were added to the culture medium. No significant somatropin-associated increase in viral burden was observed.  All patients received antiretroviral therapy for the duration of treatment during Serostim® clinical trials.

Neoplasms: Patients with preexisting tumors should be monitored for progression or reoccurrence. Monitor patients on somatropin therapy carefully for preexisting nevi.

Impaired Glucose Tolerance/Diabetes: Patients with other risk factors for glucose intolerance should be monitored closely during Serostim® therapy. Cases of new onset impaired glucose tolerance, new onset type 2 diabetes, and exacerbation of preexisting diabetes have been reported in patients receiving Serostim®. Some patients developed diabetic ketoacidosis and diabetic coma and, in some, improved when Serostim® was discontinued and in others persisted. Some of these patients required initiation or adjustment of antidiabetic treatment.

Intracranial Hypertension: Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported usually within the first 8 weeks of somatropin therapy and rapidly resolved after stopping or reducing the somatropin dose. Funduscopic examination should be performed prior to initiating treatment with somatropin and periodically during treatment. If papilledema is observed, treatment should be stopped and restarted at a lower dose after IH-associated symptoms have resolved.

Severe Hypersensitivity: Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with postmarketing use of somatropin products. Patients and caregivers should be informed that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs.

Fluid Retention/Carpal Tunnel Syndrome: Increased tissue turgor (swelling, particularly in the hands and feet) and musculoskeletal discomfort (pain, swelling and/or stiffness) may occur during treatment with Serostim®, but may resolve spontaneously, with analgesic therapy, or after reducing the frequency of dosing. Carpal tunnel syndrome may occur and if the symptoms of carpal tunnel do not resolve by decreasing the weekly number of doses, it is recommended that Serostim® treatment be discontinued.

Skin Atrophy: Rotate the injection site to avoid tissue atrophy.

Pancreatitis: Cases of pancreatitis have been reported rarely. Consider pancreatitis in patients who develop persistent severe abdominal pain.


In clinical trials in HIV‑associated wasting or cachexia the most common adverse reactions (incidence >5%) were arthralgia, myalgia, peripheral edema, arthrosis, nausea, paresthesia, generalized edema, gynecomastia, hypoesthesia and fatigue.


Somatropin should be used during pregnancy only if clearly needed and with caution in nursing mothers because it is not known whether somatropin is excreted in human milk. The safety and effectiveness of somatropin in pediatric patients with HIV have not been established.  Clinical studies did not include sufficient numbers of subjects > 65 to determine a response different from that of younger patients. Studies have not been conducted in patients with hepatic or renal impairment. Gender-based analysis is not available.


Serostim® (somatropin) for injection is indicated for the treatment of HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. Concomitant antiretroviral therapy is necessary.

Please click here full Prescribing Information.

Scroll to Top